Ikena Oncology, Inc.
USPTO PatentsView assignee record - 14 granted patents across 6 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Ikena ranks #19,890 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 6 technology areas.
- #19,890
- of 49,997 US assignees by volume
- Top 12%
- by Innovation Score (51.3/100)
- 22.1
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R19890 · US Corporation #19,890 · 14 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 14 grants
- MID-PACK #19,890/49,997
- PHOTO-FINISH Igneous Systems
- CPC-NARROW C07D · 6 areas
- INNOV-PAR 51.3/100
- CLAIMS-DENSE 22.1 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2020–2024 · 5y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Igneous Systems, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Ikena’s 51.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Ikena
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Ikena Oncology · this assignee
Ikena Oncology · this assignee
51 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Ikena's Innovation Score is 51.3/100 (top 12% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Ikena?
Each dot is one of Ikena’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ikena’s own 22.1 claims/patent is ABOVE the 14.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Ikena's grants concentrate
Ikena Oncology, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (5 grants) versus a trough of 2 in 2020. By volume, Ikena sits between ITN Energy Systems, Inc. and IncellDx, Inc..
Ikena's three-year grant acceleration
Ikena Oncology, Inc. shows 12 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Ikena's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- ITN Energy Systems
ITN Energy Systems, Inc.
14 patents
- Ixcela
Ixcela, Inc.
14 patents
- Izumi Products
Izumi Products Company
14 patents
- Igneous Systems
Igneous Systems, Inc.
14 patents
- Imagine Scientific
Imagine Scientific, Inc.
14 patents
- Immutrix Therapeu…
Immutrix Therapeutics, Inc.
14 patents
- Implant Direct Sy…
Implant Direct Sybron International LLC
14 patents
- Incelldx
IncellDx, Inc.
14 patents
- Ikena Oncology ◀
Ikena Oncology, Inc.
14 patents
What this shows Ikena holds 14 patents at rank #19,917, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Ikena
By rank, the assignees closest to #19,917 in granted patent volume.
- ITN Energy Systems, Inc. #19,913 · 14 patents
- Ixcela, Inc. #19,914 · 14 patents
- Izumi Products Company #19,915 · 14 patents
- Igneous Systems, Inc. #19,916 · 14 patents
- Imagine Scientific, Inc. #19,918 · 14 patents
- Immutrix Therapeutics, Inc. #19,919 · 14 patents
- Implant Direct Sybron International LLC #19,920 · 14 patents
- IncellDx, Inc. #19,921 · 14 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Ikena's primary technology class.
Ikena's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
51 Top 12% higher than 88% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 14.3% |
| 2022 | 3 | 21.4% |
| 2023 | 4 | 28.6% |
| 2024 | 5 | 35.7% |
Which technologies does Ikena Oncology, Inc. patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Ikena Oncology, Inc.'s patent record in context - here's where to go next.
- Ikena Oncology, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #19,890 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Ikena Oncology, Inc. against ITN Energy Systems, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 51.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.